BR0209468A - Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar - Google Patents
Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hpparInfo
- Publication number
- BR0209468A BR0209468A BR0209468-1A BR0209468A BR0209468A BR 0209468 A BR0209468 A BR 0209468A BR 0209468 A BR0209468 A BR 0209468A BR 0209468 A BR0209468 A BR 0209468A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- solvates
- pharmaceutically acceptable
- condition
- salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0111523.7A GB0111523D0 (en) | 2001-05-11 | 2001-05-11 | Chemical compounds |
| PCT/GB2002/002152 WO2002092590A1 (en) | 2001-05-11 | 2002-05-09 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209468A true BR0209468A (pt) | 2004-08-03 |
Family
ID=9914442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209468-1A BR0209468A (pt) | 2001-05-11 | 2002-05-09 | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7091237B2 (enExample) |
| EP (1) | EP1392674B1 (enExample) |
| JP (1) | JP2004534035A (enExample) |
| KR (1) | KR20040023600A (enExample) |
| CN (1) | CN1507442A (enExample) |
| AT (1) | ATE301649T1 (enExample) |
| BR (1) | BR0209468A (enExample) |
| CA (1) | CA2446797A1 (enExample) |
| CO (1) | CO5540343A2 (enExample) |
| CZ (1) | CZ20033064A3 (enExample) |
| DE (1) | DE60205481T2 (enExample) |
| ES (1) | ES2247322T3 (enExample) |
| GB (1) | GB0111523D0 (enExample) |
| HU (1) | HUP0304051A3 (enExample) |
| IL (1) | IL158332A0 (enExample) |
| MX (1) | MXPA03010285A (enExample) |
| NO (1) | NO20034986D0 (enExample) |
| PL (1) | PL367478A1 (enExample) |
| WO (1) | WO2002092590A1 (enExample) |
| ZA (1) | ZA200308352B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| WO2003016291A1 (en) | 2001-08-10 | 2003-02-27 | Nippon Chemiphar Co., Ltd. | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
| ITRM20020014A1 (it) * | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP2005035966A (ja) * | 2002-09-06 | 2005-02-10 | Takeda Chem Ind Ltd | フランまたはチオフェン誘導体およびその医薬用途 |
| AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US7504433B2 (en) * | 2003-01-06 | 2009-03-17 | Eli Lilly And Company | Thiophene derivative PPAR modulators |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| RU2374230C2 (ru) | 2003-11-05 | 2009-11-27 | Ф.Хоффманн-Ля Рош Аг | Фенильные производные в качестве ppar агонистов |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
| EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| MX2007010511A (es) * | 2005-02-28 | 2007-11-07 | Nippon Chemiphar Co | Activador para el receptor ( activador del proliferador peroxisoma. |
| US7982050B2 (en) | 2005-05-07 | 2011-07-19 | Seoul National University Industry Foundation | Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same |
| RU2007148439A (ru) * | 2005-05-25 | 2009-06-27 | Ниппон Кемифар Ко., Лтд. (JP) | Активатор для рецептора, активируемого пролифератором пероксисом |
| BRPI0616465A2 (pt) | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica |
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| US20090012133A1 (en) * | 2006-01-10 | 2009-01-08 | Smithkline Beecham Corporation | Polymorphic Form of -Acetic Acid |
| EP2014652B1 (en) | 2006-04-18 | 2014-08-06 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor |
| JO2868B1 (en) * | 2006-08-22 | 2015-03-15 | رانبكسي لابوراتوريز ليمتد | Inhibitors of metabolic protein protein enzyme |
| FR2910894A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation. |
| EP2114396A4 (en) | 2006-12-29 | 2010-03-10 | Salk Inst For Biological Studi | METHOD FOR IMPROVING TRAINING PERFORMANCE |
| JP2010519308A (ja) * | 2007-02-23 | 2010-06-03 | イーライ リリー アンド カンパニー | ペルオキシソーム増殖剤活性化受容体修飾因子 |
| US20100063041A1 (en) * | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| DE102008007400A1 (de) * | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
| MX2010011252A (es) | 2008-04-15 | 2010-11-30 | Nippon Chemiphar Co | Activador para el receptor activado por el proliferador de peroxisoma. |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| WO2014159054A1 (en) * | 2013-03-14 | 2014-10-02 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| NZ710855A (en) * | 2013-03-14 | 2020-03-27 | Dow Agrosciences Llc | Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CA3212825A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| HRP20010795A2 (en) | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
-
2001
- 2001-05-11 GB GBGB0111523.7A patent/GB0111523D0/en not_active Ceased
-
2002
- 2002-05-09 WO PCT/GB2002/002152 patent/WO2002092590A1/en not_active Ceased
- 2002-05-09 AT AT02722506T patent/ATE301649T1/de not_active IP Right Cessation
- 2002-05-09 IL IL15833202A patent/IL158332A0/xx unknown
- 2002-05-09 CZ CZ20033064A patent/CZ20033064A3/cs unknown
- 2002-05-09 US US10/476,194 patent/US7091237B2/en not_active Expired - Fee Related
- 2002-05-09 ES ES02722506T patent/ES2247322T3/es not_active Expired - Lifetime
- 2002-05-09 EP EP02722506A patent/EP1392674B1/en not_active Expired - Lifetime
- 2002-05-09 DE DE60205481T patent/DE60205481T2/de not_active Expired - Fee Related
- 2002-05-09 JP JP2002589475A patent/JP2004534035A/ja active Pending
- 2002-05-09 CN CNA028096940A patent/CN1507442A/zh active Pending
- 2002-05-09 PL PL02367478A patent/PL367478A1/xx not_active Application Discontinuation
- 2002-05-09 HU HU0304051A patent/HUP0304051A3/hu unknown
- 2002-05-09 KR KR10-2003-7014660A patent/KR20040023600A/ko not_active Withdrawn
- 2002-05-09 CA CA002446797A patent/CA2446797A1/en not_active Abandoned
- 2002-05-09 BR BR0209468-1A patent/BR0209468A/pt not_active IP Right Cessation
- 2002-05-09 MX MXPA03010285A patent/MXPA03010285A/es unknown
-
2003
- 2003-10-27 ZA ZA200308352A patent/ZA200308352B/en unknown
- 2003-11-10 NO NO20034986A patent/NO20034986D0/no not_active Application Discontinuation
- 2003-11-10 CO CO03099078A patent/CO5540343A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040157890A1 (en) | 2004-08-12 |
| KR20040023600A (ko) | 2004-03-18 |
| JP2004534035A (ja) | 2004-11-11 |
| DE60205481T2 (de) | 2006-05-24 |
| HUP0304051A2 (hu) | 2004-04-28 |
| ES2247322T3 (es) | 2006-03-01 |
| ATE301649T1 (de) | 2005-08-15 |
| CA2446797A1 (en) | 2002-11-21 |
| CO5540343A2 (es) | 2005-07-29 |
| IL158332A0 (en) | 2004-05-12 |
| PL367478A1 (en) | 2005-02-21 |
| WO2002092590A1 (en) | 2002-11-21 |
| ZA200308352B (en) | 2005-01-27 |
| EP1392674B1 (en) | 2005-08-10 |
| CZ20033064A3 (cs) | 2004-02-18 |
| NO20034986L (no) | 2003-11-10 |
| GB0111523D0 (en) | 2001-07-04 |
| NO20034986D0 (no) | 2003-11-10 |
| US7091237B2 (en) | 2006-08-15 |
| EP1392674A1 (en) | 2004-03-03 |
| CN1507442A (zh) | 2004-06-23 |
| MXPA03010285A (es) | 2004-03-09 |
| DE60205481D1 (de) | 2005-09-15 |
| HUP0304051A3 (en) | 2005-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
| BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
| BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
| BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
| BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
| BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
| BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
| SE9903544D0 (sv) | Novel compounds | |
| BR0111034A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids | |
| CY1111693T1 (el) | Αντιιικοι παραγοντες | |
| NO20034986L (no) | Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer | |
| EA200200208A1 (ru) | Синергитическая композиция | |
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| EE03969B1 (et) | (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid | |
| BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
| PT1404324E (pt) | Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida | |
| BR0311931A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente | |
| EA200300788A1 (ru) | Производные замещенных алкиламинов и их применение | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| NO20034204L (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
| EA200301142A1 (ru) | Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |